Cancer Research: NFCR Cites MHTX’s Early Cancer Detection Tech as Research Breakthrough for 2012

January 7, 2013

Click here to view the printer friendly version of this press release

ALBUQUERQUE, N.M.-- The National Foundation for Cancer Research (NFCR) has listed the SQUID-based cancer imaging technology developed by MHTX's (OTCBB: MHTX) Senior Scientific subsidiary as a "2012 Research Breakthrough." The t.echnology was developed by Edward R. Flynn, PhD, Senior Scientific’s founder and chief scientist, in collaboration with Richard S. Larson, MD, PhD, Executive Vice Chancellor UNM Health Sciences Center in New Mexico.

The NFCR has supported Dr. Robert C. Bast, Jr. of The University of Texas MD Anderson Cancer Center to collaborate with Senior Scientific in applying Senior Scientific’s technology to the early detection of ovarian cancer. The collaboration was previously press released at Dr. B.ast is a world leader in the early detection of ovarian cancer. He was responsible for the discovery of the most accurate marker for this disease, CA-125. Dr. Bast and Senior Scientific are working to apply the SQUID-based imaging technology to help save many women's lives from ovarian cancer - the notorious "silent killer" which often escapes early detection and becomes too difficult to treat when eventually diagnosed.

The technology uses Superconducting Quantum Interference Devices (SQUIDs) and non-toxic iron oxide nanoparticles to find and measure cancer and to develop new biomarkers for targeting specific cancers. It is expected to be able to detect cancer years earlier than existing techniques as well as find cancers not detectable by current methods through these new biomarkers. The technology is applicable to many cancers and has been demonstrated in application to ovarian cancer, breast cancer, prostate cancer and leukemia.

About Manhattan Scientifics

Manhattan Scientifics, Inc. ( is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.